Clinical development of Modified Vaccinia virus Ankara vaccines.

Clinical development of Modified Vaccinia virus Ankara vaccines.

Показать другие версии (1)

The smallpox vaccine Vaccinia was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one or two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is a replication-deficient and attenuated derivat...

Полное описание

Библиографические подробности
Главный автор:	Gilbert, S
Формат:	Journal article
Язык:	English
Опубликовано:	2013

Схожие документы

Clinical development of Modified Vaccinia virus Ankara vaccines
по: Gilbert, S
Опубликовано: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
по: Olga Vladimirovna Orlova, и др.
Опубликовано: (2022-09-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
по: Gilbert, S, и др.
Опубликовано: (1999)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
по: Moorthy, V, и др.
Опубликовано: (2003)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
по: Kaïdre Bendjama, и др.
Опубликовано: (2017-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
по: Volker Sandig, и др.
Опубликовано: (2013-11-01)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
по: Juan García-Arriaza, и др.
Опубликовано: (2021-08-01)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
по: Alina Tscherne, и др.
Опубликовано: (2024-11-01)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
по: López-Camacho, C, и др.
Опубликовано: (2019)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
по: Alharbi, N
Опубликовано: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
по: César López-Camacho, и др.
Опубликовано: (2019-11-01)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
по: Caroline Staib, и др.
Опубликовано: (2003-04-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
по: Harriet L. Robinson, и др.
Опубликовано: (2018-09-01)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
по: McConkey, S, и др.
Опубликовано: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
по: Rosario, M, и др.
Опубликовано: (2010)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
по: Flavia Chiuppesi, и др.
Опубликовано: (2024-02-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
по: Mingwang Shen, и др.
Опубликовано: (2024-10-01)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
по: Alharbi, N, и др.
Опубликовано: (2015)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
по: C. Staib, и др.
Опубликовано: (2000-06-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
по: Malachy I. Okeke, и др.
Опубликовано: (2017-10-01)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
по: Naif Khalaf Alharbi, и др.
Опубликовано: (2015-01-01)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
по: Moorthy, V, и др.
Опубликовано: (2003)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
по: Moorthy, V, и др.
Опубликовано: (2003)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
по: Schmidt, C, и др.
Опубликовано: (2008)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
по: Behboudi, S, и др.
Опубликовано: (2004)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
по: Schneider, J, и др.
Опубликовано: (1998)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
по: Dorrell, L, и др.
Опубликовано: (2000)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
по: Nereida Jiménez de Oya, и др.
Опубликовано: (2022-03-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
по: Hanke, T, и др.
Опубликовано: (1998)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
по: Cottingham, M, и др.
Опубликовано: (2008)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
по: Maurilia Marcacci, и др.
Опубликовано: (2020-07-01)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
по: Ning Yang, и др.
Опубликовано: (2022-10-01)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
по: Winslow, R, и др.
Опубликовано: (2017)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
по: Matthew G Cottingham, и др.
Опубликовано: (2008-02-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
по: David A Garber, и др.
Опубликовано: (2009-01-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
по: Goepfert P, и др.
Опубликовано: (2012-09-01)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
по: McConkey, S, и др.
Опубликовано: (2003)

Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.
по: Miriam Nörder, и др.
Опубликовано: (2010-01-01)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
по: Mcshane, H, и др.
Опубликовано: (2001)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
по: Hanke, T, и др.
Опубликовано: (2007)